Israel Englander Blueprint Medicines Corp Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Millennium Management LLC holds 618,787 shares of BPMC stock, worth $56.7 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

618,787

Previous 627,626 1.41%

Holding current value

$56.7 Million

Previous $67.6 Million 15.42%

% of portfolio

0.03%

Previous 0.03%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$84.1 - $120.5 $743,359 - $1.07 Million	-8,839 Reduced 1.41%	618,787 $57.2 Million
Q2 2024 Aug 14, 2024	BUY	$85.18 - $108.78 $46 Million - $58.7 Million	539,966 Added 615.98%	627,626 $67.6 Million
Q1 2024 May 15, 2024	SELL	$73.17 - $99.79 $913,527 - $1.25 Million	-12,485 Reduced 12.47%	87,660 $8.32 Million
Q4 2023 Feb 14, 2024	SELL	$43.96 - $92.84 $5.82 Million - $12.3 Million	-132,390 Reduced 56.93%	100,145 $9.24 Million
Q2 2023 Aug 14, 2023	BUY	$42.2 - $66.37 $7.37 Million - $11.6 Million	174,563 Added 301.12%	232,535 $14.7 Million
Q1 2023 May 15, 2023	SELL	$37.97 - $50.0 $10.3 Million - $13.5 Million	-270,321 Reduced 82.34%	57,972 $2.61 Million
Q4 2022 Feb 14, 2023	BUY	$41.06 - $66.48 $9.09 Million - $14.7 Million	221,486 Added 207.37%	328,293 $14.4 Million
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $3.39 Million - $5.27 Million	67,884 Added 174.41%	106,807 $7.04 Million
Q2 2022 Aug 15, 2022	SELL	$45.23 - $70.15 $5.6 Million - $8.69 Million	-123,855 Reduced 76.09%	38,923 $1.97 Million
Q1 2022 May 16, 2022	BUY	$54.1 - $110.08 $7.08 Million - $14.4 Million	130,844 Added 409.73%	162,778 $10.4 Million
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $5.33 Million - $6.56 Million	-56,517 Reduced 63.9%	31,934 $3.42 Million
Q3 2021 Nov 15, 2021	SELL	$80.98 - $109.47 $5.08 Million - $6.87 Million	-62,744 Reduced 41.5%	88,451 $9.09 Million
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $1.1 Million - $1.34 Million	13,313 Added 9.66%	151,195 $13.3 Million
Q1 2021 May 17, 2021	BUY	$90.71 - $108.28 $11.1 Million - $13.3 Million	122,680 Added 807.0%	137,882 $13.4 Million
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $18.6 Million - $25.2 Million	-202,448 Reduced 93.02%	15,202 $1.71 Million
Q3 2020 Nov 16, 2020	BUY	$66.45 - $92.7 $10.1 Million - $14.1 Million	151,788 Added 230.46%	217,650 $20.2 Million
Q2 2020 Aug 14, 2020	BUY	$57.09 - $79.27 $2 Million - $2.78 Million	35,082 Added 113.98%	65,862 $5.14 Million
Q1 2020 May 14, 2020	BUY	$48.11 - $82.22 $1.04 Million - $1.77 Million	21,514 Added 232.18%	30,780 $1.8 Million
Q2 2019 Aug 14, 2019	SELL	$73.54 - $97.8 $4.73 Million - $6.29 Million	-64,349 Reduced 87.41%	9,266 $230,000
Q1 2019 May 14, 2019	SELL	$48.7 - $86.6 $1.17 Million - $2.08 Million	-23,981 Reduced 24.57%	73,615 $5.89 Million
Q4 2018 Feb 14, 2019	SELL	$45.57 - $74.26 $1.78 Million - $2.9 Million	-39,063 Reduced 28.58%	97,596 $5.26 Million
Q3 2018 Nov 14, 2018	BUY	$58.91 - $78.32 $7.6 Million - $10.1 Million	129,085 Added 1704.32%	136,659 $10.7 Million
Q2 2018 Aug 14, 2018	SELL	$60.96 - $101.18 $3.46 Million - $5.75 Million	-56,836 Reduced 88.24%	7,574 $481,000
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $4.72 Million - $6.63 Million	64,410 New	64,410 $5.91 Million
Q4 2017 Feb 14, 2018	SELL	$62.91 - $88.32 $10.1 Million - $14.1 Million	-159,884 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $6.77 Million - $11.1 Million	159,884	159,884 $11.1 Million

Others Institutions Holding BPMC

# of Institutions

351

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.47B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account